Analysis of Factors Related to Variation in Dissolution Profiles Estimated from Continuously Conducted Dissolution Tests of Generic Products
The development of generic pharmaceuticals involves a bioequivalence study to ensure the therapeutic equivalence of the test formulation to the original innovative product. The formulation characteristics of generic products are expected to be maintained in the long term after approval. This study analyzed the factors contributing to the changes in the dissolution profiles of approved products during their life cycles. Cumulative data on the dissolution similarity of 1675 products of 127 ingredients tested by official laboratories in Japan were assessed according to Japanese bioequivalence guidelines with slight modifications. The products showing dissimilarities in dissolution profiles were analyzed for reporting year, therapeutic category, co-development, physical properties of the active pharmaceutical ingredient (API), and suspected reasons for dissolution change. The increase in the number of dissimilar products is related to the co-development of generic products. Although the solubility of the API was not associated with the dissolution change in the analysis of the total dissolution data, control of the API particle size is suggested to be important for drugs with poorly soluble APIs. Additionally, a risk factor for dissolution changes in the test solutions at a certain pH was the presence of acidic or basic residues. These results indicate the importance of proper development through a thorough evaluation of the formulation and process factors affecting the dissolution properties throughout the product lifecycle.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Chemical & pharmaceutical bulletin - 72(2024), 1 vom: 02., Seite 28-35 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morita, Tokio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioequivalence |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 05.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/cpb.c23-00647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366625225 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366625225 | ||
| 003 | DE-627 | ||
| 005 | 20240108142312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1248/cpb.c23-00647 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM366625225 | ||
| 035 | |a (NLM)38171902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morita, Tokio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of Factors Related to Variation in Dissolution Profiles Estimated from Continuously Conducted Dissolution Tests of Generic Products |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The development of generic pharmaceuticals involves a bioequivalence study to ensure the therapeutic equivalence of the test formulation to the original innovative product. The formulation characteristics of generic products are expected to be maintained in the long term after approval. This study analyzed the factors contributing to the changes in the dissolution profiles of approved products during their life cycles. Cumulative data on the dissolution similarity of 1675 products of 127 ingredients tested by official laboratories in Japan were assessed according to Japanese bioequivalence guidelines with slight modifications. The products showing dissimilarities in dissolution profiles were analyzed for reporting year, therapeutic category, co-development, physical properties of the active pharmaceutical ingredient (API), and suspected reasons for dissolution change. The increase in the number of dissimilar products is related to the co-development of generic products. Although the solubility of the API was not associated with the dissolution change in the analysis of the total dissolution data, control of the API particle size is suggested to be important for drugs with poorly soluble APIs. Additionally, a risk factor for dissolution changes in the test solutions at a certain pH was the presence of acidic or basic residues. These results indicate the importance of proper development through a thorough evaluation of the formulation and process factors affecting the dissolution properties throughout the product lifecycle | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bioequivalence | |
| 650 | 4 | |a dissolution study | |
| 650 | 4 | |a generic pharmaceutical | |
| 650 | 4 | |a quality by design | |
| 650 | 4 | |a quality management | |
| 650 | 7 | |a Drugs, Generic |2 NLM | |
| 700 | 1 | |a Yoshida, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hada, Chikako |e verfasserin |4 aut | |
| 700 | 1 | |a Nakai, Chiyori |e verfasserin |4 aut | |
| 700 | 1 | |a Kina, Keishi |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Uemura, Nozomi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoneda, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Maki |e verfasserin |4 aut | |
| 700 | 1 | |a Shintani, Yoriko |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Inagaki, Aoi |e verfasserin |4 aut | |
| 700 | 1 | |a Izutsu, Ken-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yoji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical & pharmaceutical bulletin |d 1958 |g 72(2024), 1 vom: 02., Seite 28-35 |w (DE-627)NLM000038962 |x 1347-5223 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2024 |g number:1 |g day:02 |g pages:28-35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/cpb.c23-00647 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2024 |e 1 |b 02 |h 28-35 | ||